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Background/aim: The incidence of adenoid hypertrophy is 2%–3% in children. Adenoidectomy is a commonly performed procedure in
children that may cause complications such as early or late bleeding (4%–5%), recurrence of adenoid tissue (10%–20%), and postoperative
respiratory problems (27%). Therefore, medical therapy alternatives to adenoidectomy are important and must be tried before surgery.
In this study, we investigated the efficacy of mometasone furoate, montelukast, and a combination of these drugs in pediatric patients
with adenoid hypertrophy who were scheduled for reduction with medical therapy after not being recommended for surgery.
Materials and methods: The study included 120 children with adenoid hypertrophy aged between 4 and 10 years. The patients were
randomized into 4 separate groups, with 30 in each group. Group 1 received 100 µg of mometasone furoate per day, group 2 received 4/5
mg (for age) montelukast per day, and group 3 received mometasone furoate + montelukast. Medical therapy continued for 3 months in
the treatment groups. Group 4, which comprised patients with mild symptoms, received no treatment and was the control group. The
pre- and posttreatment adenoid tissue ratios in lateral neck radiographs were recorded in the four groups.
Results: When radiologic measurements of adenoid-to-air passage were calculated, an improvement of 21.76% was observed in group 1
after treatment. The rate of improvement was 22.51% in group 2. There was a 21.79% reduction in adenoid size in group 3 after 3 months’
treatment and 12.46% in the control group. There were statistically significant differences between pre- and posttreatment values in
every single group administered corticosteroids, montelukast, and combined therapy (P < 0.05).
Conclusion: According to our results, both montelukast and mometasone furoate therapies were similarly successful in treating adenoid
hypertrophy. Combined therapy has no superiority over single-therapy treatment.
Key words: Adenoid, montelukast, mometasone furoate

1. Introduction
Adenoids are pyramid-shaped enlarged masses of
lymphoid tissue in the nasopharynx (1), and they form an
important part of Waldeyer’s tonsillar ring. Although the
adenoids are very small at birth, they may exhibit growth
in the first 4 years of life, depending on the development of
the immune system (2).
The incidence of adenoid hypertrophy is 2%–3% in
children (2). Untreated adenoid hypertrophy may lead
to difficulty in breathing through the nose, snoring, sleep
apnea, nasal speech, ear problems, growth retardation,
and craniofacial anomalies (1,2). Various methods are
used for the diagnosis of adenoid hypertrophy including
lateral head radiography, videofluoroscopy, palpation,
and nasal endoscopy; the most recent methods are lateral
radiographs and nasal endoscopy (3).
Adenoidectomy is a commonly performed procedure
in children that may cause complications such as early or
* Correspondence: birgultuhanioglu@mynet.com
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late bleeding (4%–5%), adenoid tissue recurrence (10%–
20%), and postoperative respiratory problems (27%) (2).
In addition, anesthesia risks are also among the factors
that should be taken into account (4). As such, medical
therapy alternatives to adenoidectomy are important and
must be tried before surgery.
Leukotrienes are inflammatory mediators found in
the respiratory system and these play a role in several
allergic childhood diseases (5). Cysteinyl leukotriene
receptor-1 mediates the inflammatory pathway and has
been found in high rates in postoperative adenotonsillar
tissues in pediatric patients with obstructive sleep apnea
(6–8). Montelukast is an effective and reliable cysteinyl
leukotriene receptor antagonist that can be used in oral
form and has high bioavailability. It was approved by the
United States Food and Drug Administration (FDA) for
preventive therapy against the inflammatory component
in asthma and allergic rhinitis in children aged over 1 year.
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Furthermore, montelukast has not induced tolerance in
long-term studies (9). It is used to inhibit the inflammatory
component in the disease group, which is triggered by
allergic reactions (5).
Topical nasal steroids are the most effective medical
treatment option in controlling symptoms related to
allergic rhinitis, most commonly nasal congestion (10,11).
The reliability of nasal administration of steroids in children
has been reported in a number of studies (12–14). They
penetrate the bloodstream at a low rate (0.1%) and bind
corticosteroid receptors in tissues at a high rate (15,16).
Among these medications, mometasone furoate has been
demonstrated to be the most reliable drug in children aged
over 2 years (16,17). Only a few adverse effects have been
reported, but whether this was due to poor reporting or
fewer adverse effects is not clearly known (18).
In the present study, we investigated the efficacy of
mometasone furoate, montelukast, and a combination of
these drugs in pediatric patients with adenoid hypertrophy
who were scheduled to receive reduction using medical
therapy after not being recommended for surgery.
2. Materials and methods
The study included 120 patients who presented to the
Ear, Nose, and Throat (ENT) outpatient clinic of Adana
Numune Training and Research Hospital between January
2016 and July 2016 and were diagnosed followed up for
adenoid hypertrophy. The patients were diagnosed as
having adenoid hypertrophy in the first 3 months, and
in the following months we monitored their symptoms
and nasal obstruction. Although prick tests were negative
in our patients, we preferred the months before spring
in order to minimize allergic reactions. The study was
approved by the local ethics committee of Adana Numune
Training and Research Hospital (26.04.2016/ ANEAH.
EK.2016/85). Patients aged 4–10 years of both sexes with
grades 3 and 4 adenoid hypertrophy according to the
Cassano classification were enrolled in the study (19).
Snoring, mouth breathing, and recurrent sinusitis related
to adenoiditis were the main symptoms in varying degrees.
These symptoms were scored using a scale between 0
and 10 in order to objectivize, according to information
obtained from the parents. The treatment groups were
selected randomly, and we formed a control group of
patients with mild symptoms. The same symptom scale
was used after treatment.
Patients underwent anterior rhinoscopy and flexible
nasopharyngoscopy. Children with infections, systemic
disease, craniofacial abnormalities, or genetic diseases;
those who had previously used anti-allergic drugs for
asthma or other allergic diseases; those with (+) prick
tests; those receiving immunosuppression therapy for
any reason; those recommended for surgery because

of advanced-stage nasal obstruction; those who had
previously undergone adenoidectomy; and those with
mometasone furoate hypersensitivity were excluded from
the study. We also excluded children who developed upper
respiratory tract infections during follow-up because we
know that infection can possibly increase adenoid size,
which would affect our study.
Grading of adenoidal hypertrophy was performed as
described by Cassano et al. According to this classification,
patients with 50%–75% obstruction of adenoid tissue in the
endoscopic view are grade 3 and total choanal obstruction
with adenoid tissue is grade 4. We excluded the <25%
obstruction as grade 1 and 25%–50% as grade 2 (19).
We excluded patients who had severe symptoms such as
obstructive sleep apnea that required surgery. Lateral head
radiographs were performed and assessed in all patients
included in the study. Radiographic evaluation of the
nasopharynx has been established as a simple method for
determining the size, shape, and position of the adenoids.
Evaluation of the airway was performed using lateral neck
radiographs with standard techniques in the radiology
department of our hospital. The neck was extended, and
patients were asked to breathe through their nose. The
adenoidal/nasopharyngeal ratio was measured according
to the method described by Fujioka et al. (20,21). Adenoid
tissue and the distance between the sphenobasioocciput
and the posterior end of the hard palate were measured
and proportioned (Figure 1). Lateral neck radiographs
were performed before and after 3 months of follow-up.
This study was performed as a randomized and
prospective clinical trial. Patients were divided into 4
groups, with 30 in each group. Group 1 received 1 puff of
mometasone furoate nasal spray in each nostril (50 µg/
puff) once a day, group 2 was given 4 or 5 mg (according
to age) of oral montelukast per day, group 3 was given
mometasone furoate + montelukast therapies, and group
4 received no medicine and was the control group. In
the treatment groups, medical therapy was continued for
3 months. Patients receiving treatment were called for
follow-up once per month. Patients were checked at the
each visit for treatment adherence and any adverse effects
were questioned. Lateral head radiographs were repeated
after 3 months and the adenoid tissue/air passage ratio was
measured. Pre- and posttreatment values were recorded in
all groups.
Data obtained in this study were analyzed using
SPSS 20. The Shapiro–Wilk test was used to investigate
the normality of the variables due to the unit numbers.
When the results were interpreted, significance level was
set at 0.05 with P values < 0.05 indicating variables with
nonnormal distribution, and P values > 0.05 showed
variables with normal distribution. The Kruskal–Wallis–H
test was used to analyze differences between the groups
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square analysis was used through Monte Carlo simulation
in R × C tables. The Wilcoxon test was used to analyze
differences between two dependent variables because the
variables did not show normal distribution.
When the results were interpreted, significance level
was set at 0.05 with P values < 0.05 indicating significant
difference; P > 0.05 showed no significant difference.

Figure 1. Lateral neck radiograph measuring the ratio between
adenoid tissue and the distance between the sphenobasioocciput
and the posterior end of the hard palate.

because the variables did not show normal distribution.
In the event that significant differences were obtained
from the Kruskal–Wallis–H test, the post-hoc multiple
comparison test was used to determine the groups causing
the differences. Chi-square analysis was performed to
examine the correlations of nominal variables between
the groups. Fisher’s exact test was used in the case of cells
with insufficient volumes in 2 × 2 tables, and Pearson’s chi-

3. Results
A total of 120 patients comprising 57 girls and 63 boys
who presented to the ENT outpatient clinic of Adana
Numune Training and Research Hospital were included in
the study. The ages of the patients ranged between 4 and 10
years. The mean age (±SD) was 6.97 ± 2.01 years. The mean
ages of groups 1, 2, 3, and 4 were 6.83 ± 2.05 years, 6.73 ±
2.20 years, 7.37 ± 1.85 years, and 6.93 ± 1.96 years. There
were no statistical differences between the mean ages of all
four groups. Informed written consent was obtained for
all patients. No withdrawal or treatment-related adverse
effects were observed. All patients presented (–) prick tests.
There were statistically significant differences
between the pre- and posttreatment values in the groups
administered corticosteroids, montelukast, and combined
therapy (P < 0.05). However, when compared with each
other, no statistically significant difference was found
among the three groups (Table 1; Figure 2).
There was a significant difference between the groups
regarding the change in obstruction rate (P < 0.05). The
percentage of reduction in the treatment groups was
higher than in the placebo group.
When the radiologic adenoid-to-air passage
measurement was calculated, an improvement of 21.76%
was observed in group 1 and of 22.51% in group 2 after
treatment. There was a reduction of 21.79% in adenoid size
in group 3 after 3 months’ treatment. We found the least
recovery in the untreated group at 12.46% (Table 2; Figure
3).

Table 1. Pre- and posttreatment obstruction values.
Group
n
Corticosteroid

Montelukast

Wilcoxon test
Mean

Median

Min.

Max.

SD

Mean rank

0-month obstruction ratio (%)

30

77.43

80

50

90

14.2

15.5

3-month obstruction ratio (%)

30

60.4

60

40

80

12.83

0

0-month obstruction ratio (%)

30

68.3

70

50

81

11.15

15.5

3-month obstruction ratio (%)

30

53.53

50

20

70

13.47

0

Corticosteroid +

0-month obstruction ratio (%)

30

82.33

90

50

90

11.12

15

montelukast

3-month obstruction ratio (%)

30

64.8

67.5

35

90

13.59

0

Nontreatment

0-month obstruction ratio (%)

30

71.87

70

50

90

13

14

group

3-month obstruction ratio (%)

30

63.07

65

40

90

13.53

0

1738

z

P

–4.825

0.001

–4.807

0.001

–4.775

0.001

–4.578

0.001
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Figure 2. Degrees of obstruction before and after treatments in each group.

Table 2. Kruskal–Wallis–H test results regarding reduction.
Group

n

Change in
obstruction
rate-% variation

Change of
obstruction
rate

Mean

Kruskal–Wallis–H test
Median

Min.

Max.

SD

Average

H

Corticosteroid

30

–21.76

–24.65

–33.33

–9.21

9.52

52.92

Montelukast

30

–22.51

–20.63

–60

–12.5

10.41

51.08

Corticosteroid +
montelukast

30

–21.79

–22.22

–50

0

9.8

52.78

Placebo (control)

30

–12.46

–12.5

–28.57

0

7.84

85.22

Total

120

–19.62

–20

–60

0

10.21

2–4 3–4 1–4

Corticosteroid

30

–17.03

–17

–30

–5

8.66

52.53

Montelukast

30

–14.77

–13

–30

–10

5.59

56.92

Corticosteroid +
montelukast

30

–17.54

–20

–40

0

7.71

45.97

Placebo (control)

30

–8.8

–10

–20

0

5.65

86.58

Total

120

–14.53

–12

–40

0

7.77

3–4 1–4 2–4

We observed recovery after treatment in all treatment
groups, but in the combined therapy group, the recovery
in symptom scores was statistically significant compared
with the control group (Table 3). We observed clinical
recovery from symptoms as reported by parents in all
groups, but significance only appeared in the combined
therapy group.
4. Discussion
Adenoid hypertrophy is a common disorder of
childhood. The adenoids or nasopharyngeal tonsils are
lymphoepithelial organs situated in a critical anatomic
position in the roof of the nasopharynx. Normal adenoids
attain their maximum size between the ages of 3 and

P

20.327

0.001

25.184

0.001

7 years and then regress. Hyperplasia usually follows
upper respiratory tract infection. Chronic or recurrent
infections are the two most common manifestations of
pathologic and physiologic changes in the adenoids. If
infection does not occur, adenoid tissue can regress in the
process of time (22). It leads to symptoms including nasal
obstruction, oral breathing, sleep disturbances, infections
in the ear and sinuses, and reduced quality of life. Despite
definitive treatment with adenoidectomy, adenoid tissue
may grow after infections or chronic allergic reactions,
and owing to its complications (hemorrhage, infections,
palate dysfunction, emotional stress patients and families,
and the risks of general anesthesia), alternative treatments
have emerged over time. Ren et al. reported hypernasality
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Figure 3. Difference reduction depending on treatment.
Table 3. Comparison of recovery in symptom scores after treatment between groups.
Multiple Comparisons
Measure:MEASURE_1
Group

Mean difference

Std. error

Sig.

Montelukast

0.6500

0.28639

CS + montelukast

–0.5667

Placebo

0.6500

Corticosteroid

Upper bound

0.150

–0.1188

1.4188

0.28639

0.301

–1.3354

0.2021

0.28639

0.150

–0.1188

1.4188

–0.6500

0.28639

0.150

–1.4188

0.1188

CS + montelukast

–1.2167

0.28639

0.000

–1.9854

–0.4479

Placebo

0.0000

0.28639

1.000

–0.7688

0.7688

Corticosteroid

0.5667

0.28639

0.301

–0.2021

1.3354

Montelukast

1.2167*

0.28639

0.000

0.4479

1.9854

Placebo

1.2167

0.28639

0.000

0.4479

1.9854

Corticosteroid

–0.6500

0.28639

0.150

–1.4188

0.1188

Montelukast

0.0000

0.28639

1.000

–0.7688

0.7688

CS + montelukast

–1.2167*

0.28639

0.000

–1.9854

–0.4479

Corticosteroid

Placebo

0.6500

0.28639

0.065

–0.0317

1.3317

Montelukast

Placebo

0.0000

0.28639

1.000

–0.6817

0.6817

CS + montelukast

Placebo

1.2167*

0.28639

0.000

0.5350

1.8983

Montelukast
Bonferroni
CS + montelukast

Placebo

*

*

Based on observed means.
The error term is Mean Square (Error) = 1.230.
*. The mean difference is significant at the 0.05 level.
a. Dunnett t-tests treat one group as a control, and compare all other groups against it.
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95% confidence interval
Lower bound

Corticosteroid

Dunnett t (2-sided)a

Group
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that developed due to adenoidectomy in 16 patients who
had no predisposing factors such as palatal defects (23).
In a study by Abdel-Aziz et al., 18 patients developed
velopharyngeal insufficiency after adenoidectomy. The
authors applied speech therapy to these patients for
3 months, but had to perform pharyngoplasty in 10
patients who had no response to the speech therapy (24).
Furthermore, adenoid size may increase again in children
who have undergone adenoidectomy. As with other
clinics, we sometimes encounter these complications after
performing adenoidectomies, and so what can we use as
an alternative to surgical treatment, which has so much
complications?
Intranasal corticosteroid use is one of the most
commonly published methods in the literature on this
subject. In their studies, Zhang et al. demonstrated that
intranasal corticosteroids were quite efficient in reducing
adenoid size (10). In a meta-analysis of 87 studies
conducted in children with adenoid hypertrophy, Chohan
et al. evaluated intranasal mometasone furoate in terms of
nasal symptoms, adenoid size or adenoid/choana ratio, and
improvement of otitis media with effusion and obstructive
sleep apnea, and the authors stated that it was effective (18).
Bhargava et al. used intranasal mometasone furoate in 62
patients and evaluated pre- and posttreatment adenoid
size, improvement of otitis media with effusion, which
might develop according to adenoid hypertrophy, and they
demonstrated statistical effectiveness of intranasal steroids
therapy (1). Similarly, in our study, the results of the group
that received intranasal steroid therapy indicated that it was
effective in reducing adenoid size or the adenoid choana
ratio. In a randomized, prospective study by Yılmaz et al.
of 28 adolescents aged 12–18 years, mometasone furoate
was found to be effective in reducing symptoms, but it did
not make a difference in adenoid size (25).
There are different views in the literature about
the mechanism of intranasal steroids, which provide a
reduction in adenoid hypertrophy. Demain et al. presented
a view of the regression in adenoid tissue stating that it
might be provided by intranasal steroids through a
direct lympholytic pathway, antiinflammatory impact,
or inhibition of reservoir infection (26). We suppose
that these three mechanisms may have influenced the
regression of adenoid size in our study.
Leukotrienes are inflammatory mediators active in
childhood diseases related to the respiratory system
and are among factors considered to have a role in the
pathogenesis of adenoid hypertrophy. Based on this,
leukotriene receptor antagonists can also be considered
among the alternative treatments to adenoidectomy.

In their study in children with obstructive sleep apnea,
Goldbart et al. demonstrated that a 16-week treatment
period with montelukast provided a statistically significant
reduction in adenoid size (5). In our study, we also
found regression in adenoid size in the group receiving
montelukast. Again, in another study in pediatric patients
(n = 60) with adenoid hypertrophy causing more than 75%
choanal obstruction, Shokouhi et al. observed a reduction
of 76% in the group receiving montelukast, whereas this
rate was only 3% in the placebo group (2).
Although the effectiveness of intranasal steroids or
oral montelukast has been separately investigated in a
number of studies, no study was found in the literature
comparing these two medicines on adenoid hypertrophy.
Vuralkan et al. compared intranasal mometasone furoate
and montelukast in patients with nasal polyposis and
reported no statistically significant difference between
either preparation in the reduction of symptoms, although
they found intranasal steroids were more efficient in
the prevention of polyp recurrence (27). In their study
of patients with seasonal allergic rhinitis, Martin et al.
reported that the effectiveness of intranasal steroids in
symptom reduction was statistically significant compared
with montelukast (28). In the present study, both
leukotriene antagonists and intranasal steroids separately
provided reduction in adenoid size, but we could not
demonstrate statistical superiority of one over the other.
At this point, the question could arise as to whether
combined administration of both these medications would
contribute to improvement. Friedmann and Goldman
administered combined therapy in their 4-year-old patient
whose relatives had rejected surgery. They observed that
the combined therapy was effective and reported that
surgery might be replaced by antiinflammatory therapy
in patients with mild obstructive sleep apnea (OSAS) or
postoperative residual OSA (29). In a study by Khirandish
with 22 patients, a combination of budesonide and
montelukast was administered for 12 weeks for OSAS due
to residual adenoid tissue following adenotonsillectomy
and a significant improvement in the apnea hypopnea
index was found (30). According to our results, the
combination therapy is effective at reducing adenoid size,
but superiority over montelukast or steroid alone could
not be established.
According to our results, both montelukast and
mometasone furoate therapies were similarly successful
in the treatment of adenoid hypertrophy. Both treatment
methods may separately be an alternative option to surgery
depending on treatment adherence by the patients. Larger
studies are warranted for dosage and duration of use.
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